Intra-Cellular Therapies Inc. - Common Stock (NQ:ITCI)

131.87 UNCHANGED

Last Price Updated: 4:00 PM EDT, Apr 1, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Intra-Cellular Therapies Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Benzinga's Top Ratings Upgrades, Downgrades For July 7, 2022 ↗

July 07, 2022

Upgrades

Via Benzinga

Robust Uptake Of Antipsychotic Drug Boosts Intra-Cellular's Q1 Earnings ↗

May 10, 2022

Via Benzinga

Earnings Scheduled For March 1, 2022 ↗

March 01, 2022

Companies Reporting Before The Bell • Precigen (NASDAQ:PGEN) is expected to report earnings for its fourth quarter. • TG Therapeutics (NASDAQ:TGTX) is estimated...

Via Benzinga

Intra-Cellular Therapies Inc. (ITCI): The Winning Streak Continues

February 16, 2022

Via Investor Brand Network

Intra-Cellular Therapies Inc. (ITCI): The Winning Streak Continues

February 16, 2022

Via Investor Brand Network

Analyst Ratings for Intra-Cellular Therapies ↗

July 07, 2022

Over the past 3 months, 4 analysts have published their opinion on Intra-Cellular Therapies (NASDAQ:ITCI) stock. These analysts are typically employed by large Wall Street banks and tasked with...

Via Benzinga

INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Intra-Cellular Therapies, Inc. with Losses to Contact the Firm

June 16, 2022

From The Schall Law Firm

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For June 14, 2022 ↗

June 14, 2022

Upgrades

Via Benzinga

Looking Into Intra-Cellular Therapies's Return On Capital Employed ↗

June 09, 2022

According to Benzinga Pro data, during Q1, Intra-Cellular Therapies (NASDAQ:ITCI) posted sales of $35.00 million. Earnings were up 15.88%, but Intra-Cellular Therapies still reported an overall loss of...

Via Benzinga

Intra-Cellular Therapies Stock Clears Technical Benchmark, Hitting 90-Plus RS Rating ↗

May 11, 2022

Intra-Cellular Therapies stock cleared a key performance benchmark, with its Relative Strength (RS) Rating, rising to 97.

Via Investor's Business Daily

77 Stocks Moving In Tuesday's Mid-Day Session ↗

May 10, 2022

Gainers

Via Benzinga

103 Biggest Movers From Yesterday ↗

May 11, 2022

Gainers

Via Benzinga

The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves ↗

May 10, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Recap: Intra-Cellular Therapies Q1 Earnings ↗

May 10, 2022

Intra-Cellular Therapies (NASDAQ:ITCI) reported its Q1 earnings results on Tuesday, May 10, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

What 4 Analyst Ratings Have To Say About Intra-Cellular Therapies ↗

April 21, 2022

Analysts have provided the following ratings for Intra-Cellular Therapies (NASDAQ:ITCI) within the last quarter:

Via Benzinga

Intra-Cellular Therapies's Return On Capital Employed Insights ↗

March 04, 2022

Intra-Cellular Therapies (NASDAQ:ITCI) brought in sales totaling $25.67 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 11.48%, resulting...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For April 22, 2022 ↗

April 22, 2022

Upgrades

Via Benzinga

What 6 Analyst Ratings Have To Say About Intra-Cellular Therapies ↗

March 02, 2022

Analysts have provided the following ratings for Intra-Cellular Therapies (NASDAQ:ITCI) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish...

Via Benzinga

Intra-Cellular Therapies: Q4 Earnings Insights ↗

March 01, 2022

Intra-Cellular Therapies (NASDAQ:ITCI) reported its Q4 earnings results on Tuesday, March 1, 2022 at 08:00 AM. Here's what investors need to know about the announcement...

Via Benzinga

Stocks That Hit 52-Week Highs On Thursday ↗

April 07, 2022

On Thursday, 75 stocks made new 52-week highs. Interesting Highlights From Today's 52-Week Highs: The largest company by market cap to hit a new 52-week high...

Via Benzinga

The Daily Biotech Pulse: Legend Biotech, CTI Biopharma Receive FDA Approvals, AbbVie Announces Delay In Skyrizi Review, Editas Gains On CRISPR Patent Resolution ↗

March 01, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Editas Gains On Resolution Of CRISPR Gene Editing Patent Case Editas Medicine...

Via Benzinga

The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight ↗

February 27, 2022

Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first...

Via Benzinga

Where Intra-Cellular Therapies Stands With Analysts ↗

February 16, 2022

Analysts have provided the following ratings for Intra-Cellular Therapies (NASDAQ:ITCI) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish...

Via Benzinga

Expert Ratings For Intra-Cellular Therapies ↗

February 16, 2022

Within the last quarter, Intra-Cellular Therapies (NASDAQ:ITCI) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish...

Via Benzinga

Intra-Cellular Therapies Inc.: The Winning Streak Continues ↗

February 16, 2022

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Intra-Cellular Therapies Inc. (NASDAQ:...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For February 16, 2022 ↗

February 16, 2022

Upgrades According to Compass Point, the prior rating for Comerica Inc (NYSE:CMA) was changed from Neutral to Buy. Comerica earned $1.66 in the fourth quarter, compared to $1.49...

Via Benzinga

New Psychedelics ETF Launches On NYSE Arca ↗

February 02, 2022

Elemental Advisors Inc. has launched its first ETF, composed of companies involved in research, development, production or use of psychedelics to address medical conditions. The PSYK ETF (NYSE: PSYK)...

Via Benzinga

53 Biggest Movers From Friday ↗

January 24, 2022

Gainers Blue Star Foods Corp. (NASDAQ: BSFC) shares climbed 100% to close at $3.80 on Friday after gaining around 9% on Thursday. Dave Inc. (NASDAQ: DAVE) jumped 30.3% to settle...

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

January 21, 2022

Gainers Biophytis (NASDAQ:BPTS) shares rose 12.3% to $5.28 during Friday's regular session. The market value of their outstanding shares is at $68.0 million. Intra-...

Via Benzinga

34 Stocks Moving In Friday's Mid-Day Session ↗

January 21, 2022

Gainers Blue Star Foods Corp. (NASDAQ: BSFC) shares jumped 180% to $5.32 after gaining around 9% on Thursday. Bon Natural Life Limited (NASDAQ: BON) shares gained 22% to $3.91....

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.